Melanoma
Efficacy and Safety of First-Line Nivolumab Combinations in Melanoma
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
Efficacy and Safety of First-Line Nivolumab Combinations in Melanoma
ASCO 2024: Efficacy and Safety of Triplet in Advanced Melanoma
Pembrolizumab as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma
Pembrolizumab vs Ipilimumab in Advanced Melanoma: Long-Term Follow-up
Mediterranean Diet and Outcomes Among Patients With Advanced Melanoma Receiving Immunotherapy
Subset of Patients With a Very Low Risk of Dying From Melanoma
ESMO 2022: SWOG S1801 Trial of Timing of Pembrolizumab in Resected Advanced Melanoma
UV-Protective Behaviors Among American Indians and Alaskan Natives
Rapid Recommendation Update to ASCO Guideline for Systemic Treatment of Melanoma
Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
Relatlimab and Nivolumab vs Nivolumab Alone in Untreated Advanced Melanoma